Lotta Ferm, interim CFO of Immunicum AB, was now named as Chief Financial Officer.
Pfizer Inc announced it will allow generic makers in 95 low income nations to produce and distribute its COVID-19 pill Paxlovid at cost price.
London-based Synthace, which develops software to automate biology experimentation, has raised US$35m in a Series C from notable investors.
The COVID-19 pandemic created exceptional circumstances for virologists. To speed up the process from initial basic experiments to the final clinical application, appropriate reagents are required. Isolation of SARS-CoV-2-specific T cells via the MHC Streptamer® approach yields label-free, fully functional cells, making this method a valuable tool for high quality research.
BIAL, a public limited company under Portuguese law with head office in Coronado, Portugal, appointed Joerg Holenz as R&D General Manager and as a member of the Board of Directors.
The EU has secured 60 million doses of Valnevas potential Covid-19 vaccine VLA2001. When approvied, it would be the first inactivated vaccine on the EU market.
By applying the expertise, best practice, and emerging technologies of the logistics industry, biotech not only prevents the missteps that can destroy its products, it can also capitalise on opportunities to get to new markets faster, safer and more cost effectively.
Life Sciences investor LSP is set to being acquired by Europe’s largest equity specialist EQT AB.
Two European oncology biopharma companies have made the leap onto the stock market: French MaaT Pharma went public on Euronext Paris, while Danish IO Biotech chose Nasdaq Global Market for its IPO.
European life science investor LSP has raised €850m for its 7th generation flagship fund LSP 7.